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Background: Hyaluronic acid is a prognostic factor in ovarian cancers. It is also a component of Hyaluronic
Acid-Carboxymethyl Cellulose (HA-CMC) barrier, an anti-adhesion membrane widely used during abdominal surgeries
in particular for ovarian carcinosis. 70% of patients who undergo ovarian surgery will relapse due to the persistence of
cancer cells. This study’s objective was to determine the oncological risk from use of this material, in the presence
of residual disease, despite the benefit gained by it decreasing post-surgical adhesions in order to provide an
unambiguous assessment of its appropriateness for use in ovarian surgical management.
Methods: We assessed the effects of HA-CMC barrier on the in vitro proliferation of human ovarian tumor cell lines
(OVCAR-3, IGROV-1 and SKOV-3). We next evaluated, in vivo in nude mice, the capacity of this biomaterial to
regulate the tumor progression of subcutaneous and intraperitoneal models of ovarian tumor xenografts.
Results: We showed that HA-CMC barrier does not increase in vitro proliferation of ovarian cancer cell lines
compared to control. In vivo, HA-CMC barrier presence with subcutaneous xenografts induced neither an increase
in tumor volume nor cell proliferation (Ki67 and mitotic index). With the exception of an increased murine
carcinosis score in peritoneum, the presence of HA-CMC barrier with intraperitoneal xenografts modified neither
macro nor microscopic tumor growth. Finally, protein analysis of survival (Akt), proliferation (ERK) and adhesion
(FAK) pathways highlighted no activation on the xenografts imputable to HA-CMC barrier.
Conclusions: For the most part, our results support the lack of tumor progression activation due to HA-CMC
barrier. We conclude that the benefits gained from using HA-CMC barrier membrane during ovarian cancer
surgeries seem to outweigh the potential oncological risks.
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Ovarian cancer is the leading cause of mortality among
the gynecological diseases occurring in developed coun-
tries with 225,500 new cases and 140,200 estimated
deaths worldwide [1,2]. This high rate of mortality is due
in part because most patients presenting epithelial ovar-
ian cancer have an advanced disease at the time of diag-
nosis [1]. After surgical resection, residual disease then* Correspondence: couderc.bettina@claudiusregaud.fr
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unless otherwise stated.represents the major pejorative predictive factor for
survival [2]. For optimum results, surgery must be as
complete as possible which generally means perform-
ing en-bloc resections of bowel, reproductive organs
and genital tract, and peritonectomies.
The corollary of these “radical” surgeries is the induction
of intra-abdominal adhesions that lead to the sticking
together of two tissues normally moving freely past each
other. As well as causing bowel obstruction and chronic
pain, these adhesions can also induce heterogeneity of
drug diffusion and compromise the delivery of adjuvant
intraperitoneal chemotherapy [3]. Moreover, they can
complicate any new surgical procedures, which in ovarianLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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recurrence (70%). The place of secondary cytoreductive
surgery is actually evaluated in several clinical trials with a
complete resection as a gold standard. It is clear therefore
that the reduction of adhesive disease has many immedi-
ate and delayed functional and therapeutic consequences
in ovarian cancer bearing patients. An exhaustive review
published by Ward B.C describes all adhesion prevention
strategies including non-invasive surgical strategies,
cellular strategies, pharmaceutical approaches, fluid
and gel barriers, and lastly solid barriers including
Hyaluronic Acid-Carboxymethyl Cellulose (HA-CMC)
barrier [4].
HA-CMC barrier is an implantable and bioabsorb-
able synthetic membrane, composed of hyaluronan (also
called hyaluronic acid or HA) and carboxymethylcellulose
(CMC) which turns into a gel within 24 hours, before
being absorbed from the surgical site within one week
for elimination from the organism in less than 30 days.
It became available in France in 2003 for indications of
benign abdominal surgeries and since 2007, following
Oikonomakis [5] and Kusonoki’s publications [6] for re-
spectively colon and rectal cancers, is also used for car-
cinologic surgeries. Since then, many preclinical, animal
and clinical works studying HA-CMC barrier in digestive
cancers have been published. A meta-analysis performed
by Diamond MP describes this material as « biocompat-
ible, non-mutagenic, non-pyrogenic, non-irritating and
non-toxic » [7]. However, some animal studies have given
contradictory results revealing no effect of HA-CMC
in colon tumor metastasis but a local increase in tumor
growth [8], and in some cases, an increase in rate of
abdominal metastasis [9].
The major component of HA-CMC barrier, HA, is a
physiological component of extracellular matrix in asso-
ciation with collagen, proteoglycans (such as fibronectin,
laminin and vitronectin) and elastin. Its main receptor is
CD44 which is present at the surface of various normal
or tumor cells. Another HA receptor, CD168, also called
receptor hyaluronic acid mediated motility (RHAMM),
has been described in CD44 knock-out mice [10]. The HA
expression level is modified in the context of ovarian can-
cer and high levels are correlated with poor prognosis
[11]. In histological retrospective studies, tumor stromal
HA concentration has been linked with tumor aggressive-
ness, and stromal HA has been shown to be an independ-
ent prognostic factor for disease free and overall survival
[12,13]. Moreover, high level of HA synthase 1 (HAS1),
but not HAS2 and HAS3, is correlated with reduced
overall survival in ovarian cancer [14]. Furthermore, CD44
expression level of ovarian cancer cells is inversely propor-
tional to patient survival [15].
Many studies, mainly in vitro, have allowed us to define
more precisely the implication of HA in ovarian cancer.As an example, HA from mesothelial cells, the major cell
population in the peritoneum, is an adhesion factor for
CD44-positive ovarian cancer cells [16]. These data have
been confirmed by adhesion tests using hyaluronidase,
anti-CD44 antibodies and CD44 targeted siRNA [17-19].
Mesothelial extracellular HA is also involved in ovarian
carcinoma cell motility and dose-dependent chemotact-
ism. Indeed, Boyden chamber tests highlighted than ovar-
ian cancer cells preferentially migrate towards mesothelial
cells as compared to control conditions, and that this
effect is abolished using hyaluronidase [20]. Moreover,
HA-CD44 interaction in SKOV-3 ovarian cancer cells
can induce F-actin oriented polymerization using two
signaling pathways involving Src or N-WASP [20-22].
Among non-gynaecological cancers, a retrospective
study showed that HA-CMC barrier use has been asso-
ciated with a 13% increased risk of abscess after colec-
tomy [23]. On the contrary, HA-CMC barrier has not
been showed to be associated with increased complica-
tions in thyroid surgery despite an uncertain anti-adhesive
effect [24].
While some studies regarding HA-CMC barrier utilization
in gynecological surgery have been published [25-29]
none describe the potential effects of this biomaterial in
ovarian metastatic process in animals. Of the mainly
clinical studies, most are retrospective. Only one is pro-
spective including 14 patients with HA-CMC barrier,
and concern in half of the cases cervical and uterine
cancers. Krill et al. evaluated the risk of postoperative
complications related to HA-CMC utilization in ovarian
cancers after cytoreductive surgery and showed that this
biomaterial is not responsible for major complications
but may be associated with increased risk of pelvic abscess
[30]. However, they did not study the effects of HA-CMC
on ovarian cancer progression and recurrence.
Our concern was to evaluate the potential effect of
HA-CMC in a context where residual cancer cells were
present. Indeed, after ovarian surgery, and because 70%
of patients will relapse, it is clear that those cells could
be affected by HA-CMC presence.
Accordingly, we decided to perform a preclinical study
in order to evaluate HA-CMC barrier impact on ovarian
tumor progression. In vitro experimentations were per-
formed to analyze the effects of HA-CMC barrier on the
proliferation of several ovarian cancer cell lines and on
the activation of proliferative, survival and adhesion
signaling pathways. In vivo mice xenograft models were
used to evaluate the oncological risk of HA-CMC barrier
utilization in comparison with expected benefits from
adhesion prevention. Our ultimate aim was to provide
a clear assessment of the appropriateness of using HA-
CMC barrier in the surgical management of ovarian
cancer. We demonstrated that in vitro, HA-CMC bar-
rier did not increase tumor cell proliferation and that
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HA-CMC barrier membranes and absorbable material
were granted from the surgical department of Claudius
Regaud Institute (Toulouse France) without industrial
founds.
Cell culture
NIH ovarian adenocarcinoma cells (OVCAR-3 and SKOV-3)
and HeLA cells were obtained from the American Type
Culture Collection (ATCC® numbers HTB-161, HTB-77
and CCL-2). IGROV-1 ovarian adenocarcinoma cells
were a gift from the Gustave Roussy Institute (Villejuif,
France) and the REH lymphoblastic line was a gift from
the hematology research unit of Toulouse University
Hospital (France). All cells were cultured in RPMI
medium supplemented with 10% fetal calf serum (FCS),
penicillin/streptomycin (100 IU/mL/100 μg/mL) and
2 mM L-glutamine (Cambrex biosciences, Milan, Italy).
Cell lines were routinely checked for mycoplasma.
Cell proliferation
OVCAR-3, IGROV-1 and SKOV-3 cells were seeded in
6-well plates at a concentration of 2 × 105 cells per well.
Three different conditions were used: culture with RPMI
alone or with 1 cm2 pieces of HA-CMC barrier or a control
absorbable material. Cell proliferation kinetics was assessed
by counting cells on a hemocytometer after 1, 2, 4 and
6 days of culture. Cell population doubling time during
the exponential growth phase was calculated according
to the following formula: T(hours) = t × [ln(2)/[ln(C1) ‐ ln
(C0)]] in which t corresponds to the exponential growth
phase in hours, C0 to the initial cell concentration at the
beginning of this phase and C1 to the final cell concentra-
tion at the end of the phase.
CD44 expression evaluation by flow cytometry
Each cell line (106 OVCAR-3, IGROV-1, SKOV-3,
HeLA or REH lymphoblast cells) was incubated during
45 minutes with a primary antibody directed against
CD44 (1/100, [F10-44-2] (ab6124), Abcam, Paris, France),
or against a control isotype (κ isotype Ctrl PE Mouse
IgG1, BioLegend). Cells were then washed with PBS, cen-
trifuged 5 minutes at 300 g, then incubated 45 minutes
with an anti-mouse secondary antibody (1/50, BD Bio-
sciences, Le pont de Claix, France). Cells were washed
with PBS and the fluorescence was measured with a
FACS Calibur cytometer and analyzed with Cell Quest
Pro software.Animals
Four to five week-old female Swiss Nude athymic mice
(Charles River laboratories, l’Abresle, France) were used
after approval from Claudius Regaud Institute animal
ethics committee (ICR-2012-017). They were housed
according to the European Laboratory Animal Science
Association standards. Mice experimentations began after
one week of quarantine.
HA-CMC barrier mouse absorption validation
A 2.25 cm2 (15 × 15 mm) piece of HA-CMC barrier was
inserted into the abdomens of mice by median laparotomy
after intraperitoneal general anesthesia (ketamine 50 mg/mL,
xylazine 20 mg/mL and NaCl: 10 μg per gram of mouse).
Mice were then sacrificed via cervical dislocation 1, 3 or
7 days after surgery in order to proceed to histological
analysis.
Subcutaneous (s.c.) xenografts
107 SKOV-3 cells were injected subcutaneously into
each of the right and left flanks of 16 mice. The day fol-
lowing this injection (D1), after cutaneous debridement
with chlorhexidine, an incision was made under general
anesthesia at the two injection sites and a 1 cm2 (10 ×
10 mm) piece of HA-CMC barrier was alternatively
inserted into one of the two sites. The other side was
opened and then closed to reproduce the inflammation
caused by the surgical procedure. The well-being of the
mice was checked every 2 to 3 days. Tumor lengths (L)
and widths (w) were also measured every two to three days
and the tumor volume extrapolated using the formula:
(π × length × width2)/6. Mice were sacrificed 21 days via
cervical dislocation after the injection. Tumors were
sampled then conditioned for histological analysis (for-
mol fixation) or western blot (cryopreservation in liquid
nitrogen).
Intraperitoneal (i.p.) xenografts
2.5 × 107 SKOV-3 cells were injected intraperitoneally
into each of 22 mice. The day following the injection
(D1), after cutaneous debridement with chlorhexidine, a
laparotomy was performed under general anesthesia
according to one of two procedures: (A) 11 mice under-
went a “white” laparotomy (incision, abdominal opening
and closure) and (B) 11 mice received an i.p. 2.25 cm2
(15 × 15 mm) piece of HA-CMC barrier. For both
groups, parietal closure consisted in three separate ab-
sorbable material 3/0 sutures. The well-being of the
mice was checked during 21 days and their weight was
measured three times a week. The mice were sacrificed
by cervical dislocation 21 days after the injection of cells.
Autopsies were then performed by two double-blinded
specialist surgeons in ovarian cancer surgery to evaluate
Picaud et al. Journal of Ovarian Research 2014, 7:40 Page 4 of 12
http://www.ovarianresearch.com/content/7/1/40the abdominal carcinosis index and tumors were removed
for histological and western blot analysis.
Histological analysis, Ki67 staining and mitotic index
determination
Proliferative indices of tumor from s.c. or i.p. injections
were assessed by immunohistochemical staining of paraf-
fin embedded tumor sections for the proliferation marker
Ki67 using mouse monoclonal MIB1 antibody. Ki67 posi-
tive nuclei were counted in random fields. The mitotic
index was assessed by evaluating the number of cells in
mitosis per high-power field (10 high-power fields per
tumor).
Western blot
Western blot was performed to evaluate in vitro protein
expression in CD168 cell lines and to analyze in vivo the
activation of signaling pathways within the xenografts. In
vitro, proteins in OVCAR-3, IGROV-1, SKOV-3, HeLa
and REH lymphoblastic cells were studied. In vivo, cryo-
preserved xenograft tumors were pooled according to
protocol (subcutaneous versus intraperitoneal, with or
without HA-CMC barrier). Cells and tumor samples were
crushed then prepared with RIPA lysis buffer (Tris 1 M at
pH 7.4, NaCl 150 mM, Triton, SDS 20%, MgCl2, NaF and
protease inhibitors). The concentration of proteins was
determined using the « Bradford Assay » (Bio-Rad) before
their separation by SDS-PAGE in a 10% polyacrylamide
gel and transfer onto a PVDF membrane (Amersham
Hybond) previously activated with methanol. These mem-
branes were saturated 45 minutes in TBS (50 mM Tris,
150 mM NaCl) / Tween 0.2% (TBST) supplemented with
5% milk and then incubated 90 minutes with a rabbit pri-
mary antibody against CD168 (1/1000, ab108339, Abcam)
for cells lines, or Akt, p-Akt, p-ERK or FAK (1/1000, Cell
Signaling Technology) for tumor samples. Membranes
were washed three times with TBST and incubated
90 minutes with an anti-rabbit secondary antibody
coupled with horseradish peroxidase (HRP) (1/2000,
Cell Signaling Technology, St Quentin, France). Mem-
branes were washed three times with TBST and twice
with TBS before immunocomplexes were revealed with
Enhanced Chemoluminescence (GE Healthcare) and vi-
sualized with a photon camera (Bio-Rad).
Statistics
Quantitative variables were presented by median and
range and qualitative data by frequency and percent.
Group comparisons were made using the Wilcoxon
signed rank test (matched) or Mann–Whitney test (inde-
pendent) for non-parametric data and by the Student’s t
test for parametric ones. For this entire study, statistical
significance was reached for p < 0.05. In vivo, with a
standard deviation of 0.1, to reach a statistical differencemean of 15% in terms of tumor proliferation with a statis-
tical power of 80% and α risk of 5%, 22 mice per experi-
mentation were necessary. All analyses were performed
using STATA software (Version 12.0; Stata Corporation,
College Station, TX, USA).Results
HA implication in ovarian tumor progression has already
been described. The goal of this study was to determine
whether HA-CMC barrier, being mainly composed of HA,
was implicated in ovarian tumor progression and spread.OVCAR-3, IGROV-1 and SKOV-3 ovarian cancer cells
express CD44 and CD168
OVCAR-3, IGROV-1 and SKOV-3 cell lines differ in
terms of their genetic alteration and chemosensitivity. In
order to confirm the capacity of these cells to interact
with HA-CMC barrier, we firstly studied their expression
of HA receptors, CD44 and CD168 by respectively flow
cytometry (Figure 1A) and western blotting (Figure 1B).
As a negative control of CD44 expression, we used REH
lymphoblast cells and as our positive control HeLa cells.
REH lymphoblast cells and HeLa cells constituted our
positive control for CD168 expression. All three ovarian
cancer cell lines were shown to express both CD44 and
CD168.HA-CMC barrier does not promote OVCAR-3, IGROV-1 or
SKOV-3 ovarian cancer cell proliferation in vitro
To evaluate the effect of HA-CMC barrier on ovarian can-
cer cell proliferation, OVCAR-3, IGROV-1 and SKOV-3
cells were seeded in medium alone or with 1 cm2 pieces of
HA-CMC barrier or a control absorbable material which
is a biomaterial used in abdominal surgery that, as an
added exogenous material induces inflammation in vivo.
In vitro, absorbable material was used as a control for bio-
material presence. We used an hemocytometer to count
the cells for each condition 1, 2, 4 and 6 days after seeding
(Figures 2A, B and C) and calculated the doubling time
for each cell line during the exponential proliferative phase
between the 2nd and 4th day (Figure 2D).
Comparison to the control condition (RPMI medium
alone) revealed a lack of any cell proliferation induced by
either HA-CMC barrier or absorbable material (Figure 2A,
B and C). Indeed, less cells could be defined at day 6 in
the HA-CMC barrier group even though there was no
statistical difference regarding cell line doubling times
between the 2 conditions.
Absorbable material absorption was longer than that
for HA-CMC barrier which, considering the potential
to lead to chronic inflammation in mice, we decided to
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Figure 1 CD44 and CD168 expression in ovarian cancer cell lines. (A) The CD44 expression was measured by flow cytometry and analyzed
with Cell Quest Pro software in ovarian cancer cell lines OVCAR-3, IGROV-1 and SKOV-3 as well as in REH lymphoblasts (negative control) and
HeLa cells (positive controls). The auto fluorescence level was determined with an isotype control antibody (empty area). The CD44 expression
was determined with an anti-CD44 antibody (full area) leading to the determination of the percentage of CD44 positive cells (M1). (B) The CD168
level was determined by western blot using a specific antibody in ovarian cancer cell lines OVCAR-3, IGROV-1 and SKOV-3 as well as in REH
lymphoblasts and HeLa (positive controls). Immunocomplexes were visualized with a photon camera.
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Figure 2 Effects of HA-CMC barrier on ovarian cancer cell line proliferation in vitro. (A, B, C) Ovarian cancer cell lines OVCAR-3 (A), IGROV-1
(B) and SKOV-3 (C) were cultured in the presence of control medium (RPMI), 1 cm2 of control absorbable material, or 1 cm2 of HA-CMC barrier. After 1,
2, 4 and 6 days of culture, cell number was counted with a hemocytometer. (Mean number of cells +/− SEM, n = 3). (D) Doubling times were
calculated from previous proliferation curves according to the following formula: doubling time (hours) = t x [ln (2) / [ln (C1) – ln (C0)]] with t
corresponding to the duration of the exponential phase, C0 to the initial cell concentration and C1 to the final cell concentration (between the
beginning and the end of the exponential phase). (Mean doubling time +/− SEM, n = 3).
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and women
In order to evaluate whether the HA-CMC barrier absorp-
tion in mice is representative of that occurring in humans,
we performed a laparotomy and place HA-CMC barrier
pieces into the abdomen of mice. The mice were then
sacrificed 1, 3 or 7 days after surgery before histological
analysis of the surgical site was performed in order to ob-
serve the biomaterial presence (Figure 3). After one day,
HA-CMC barrier was present as an amorphous and cell-
free material in association with numerous neutrophilic
polynuclear cells (acute inflammatory reaction). After
3 days, HA-CMC barrier persisted as subperitoneal sedi-
ment and the acute inflammatory reaction was associated
with mesothelial hyperplasia. At day 7, HA-CMC barrier
remaining under the peritoneum had been mostly ab-
sorbed, and an inflammatory phase going into the prolifer-
ative phase of wound healing was evident by the presence
of fibroblasts and macrophages at the peritoneal surface.
Subcutaneous (s.c.) xenografts
To determine the potential role of HA-CMC barrier in
ovarian tumor growth, we established SKOV-3 cell s.c. xe-
nografts in mice in both flanks. The day following this in-
jection, we made an incision at the two injection sites and
placed a 1 cm2 piece of HA-CMC barrier, proportionally
similar to the mean surface area during human ovarian
cancer surgery, randomly into one of the two flanks, the
other side simply being closed again to reproduce the in-
flammation caused by the surgical procedure. Tumor vol-
ume, as extrapolated from the measurement of tumor
length and width every 2 or 3 days (Figure 4A), showed no
increase in the presence of HA-CMC barrier by compari-
son with control. Median tumor volume in fact showed a
greater variation between days 12 and 21 in the control
group than in the HA-CMC barrier group (p = 0.0288).
Histological analysis of all tumor samples showed that by
comparison with the control group, the HA-CMC barrier
group had neither an increased mitotic index (Figure 4B)
nor Ki67 marking (Figure 4C), highlighting that this bio-
material had no effect on the growth of the s.c. ovarian
tumor xenograft.
Intraperitoneal (i.p.) xenografts
In order to study the possible effect of HA-CMC barrier
on ovarian tumor peritoneal dissemination, we thenestablished i.p. SKOV-3 cell xenografts in mice. The day
following the injection, mice underwent a “white” lapar-
otomy (incision, abdominal opening and closure) or a
laparotomy with an i.p. implementation of a 2.25 cm2
piece of HA-CMC barrier. These mice were sacrificed
by cervical dislocation 21 days after this injection before
two surgeons, specialists in ovarian cancer surgery, per-
formed an autopsy to evaluate murine carcinosis index
(MCI) per organ (Table 1). We modified a previously
published endoscopic murine score of carcinosis [31],
that made it applicable to macroscopic analysis.
Total MCI score ¼ nodule maximal diameter score
 nodule number score
Our results showed that HA-CMC barrier induced no
increase in MCI in the diaphragm, liver or digestive tract
by comparison with the control group. However, HA-
CMC barrier was responsible for a significantly higher
MCI score (30 compared to 15, p = 0.0349) in the anter-
ior and lateral peritoneum (excluding the diaphragmatic
cupola) compared to the control group (Figure 5A).
Histological analysis revealed no statistical difference
between HA-CMC barrier and control groups with regards
mitotic index (Figure 5B) or percentage of Ki67 positive
cells (Figure 5C).
HA-CMC barrier does not activate MAP kinase, Akt or FAK
pathways in i.p. or s.c. ovarian tumor xenografts
With regards the participation of peritumoral stroma
and microenvironment cells, except for the increase in
MCI in the anterior and lateral peritoneum, we observed
no phenotypical modifications concerning proliferation,
growth and tumor dissemination caused by HA-CMC
barrier. To investigate potential molecular effects of this
biomaterial on ovarian tumor cells, we assessed the activa-
tion of cell signaling pathways implicated in cell survival
(Akt and phospho-Akt), proliferation (phospho-ERK, the
terminal kinase of the MAP-kinase pathway), and adhe-
sion (FAK). Our results show that HA-CMC barrier did
not modify the level of Akt or FAK and did not induce
phosphorylation of Akt or ERK when compared to the
control group (Figure 6). Therefore, on the basis of studied
proteins, it appeared that HA-CMC barrier did not induce







Figure 3 Evolution of the HA-CMC barrier absorption in nude
immunosuppressed mice. After general anesthesia and cutaneous
debridement, a 15 x 15 mm piece of HA-CMC barrier was placed in
mice abdomens. 1 (D1), 3 (D3) and 7 (D7) days after surgery, mice
were sacrificed and abdominal walls were analyzed by histology
(hematein-eosin coloration). HA-CMC barrier pieces or residues were
marked with a star (*).
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Discussion
Complete cytoreductive surgery for advanced ovarian
cancer can induce extended abdominal adhesions. These
adhesions may prevent optimal intraperitoneal treatment
delivery and can cause bowel obstruction and pain. The
need to prevent such adhesions during abdominal sur-
gery is a unanimously agreed objective. Among the solid
barriers placed to decrease adhesive disease, HA-CMC
barrier is one of the most widely used, and yet its essen-
tial component HA is a prognostic factor of survival in
ovarian cancer bearing patients. Despite our in-depth
study of the literature, we found no conclusive data re-
garding the oncological risk of using HA-CMC barrier
in these patients.
Our results show that HA-CMC barrier does not acti-
vate the proliferation of the ovarian tumor cells OVCAR-3,
IGROV-1 or SKOV-3 in vitro. Moreover, it cannot be
excluded that the biomaterials may have actually acted
as a physical constraint of cell proliferation. Indeed,
whether the biomaterial used was HA-CMC barrier or
an absorbable material, cell proliferation was less active
than without the biomaterial. Particularly with IGROV-1
cells, HA-CMC seemed to present an anti-proliferative
effect. Observing the same number of IGROV-1 cells in
each condition at day 1 (Figure 2B and D), we did not
conclude on an anti-adhesive effect of HA-CMC barrier
on IGROV-1 cells. Considering that in vitro experiments
exclude microenvironment participation, we studied in vivo
the potential implication of HA-CMC barrier in ovarian
tumor progression in mice.
Nearly all the results obtained in vivo, whether they
concerned subcutaneous tumor cell injections (tumor
volume, mitotic index or Ki67 percentage) or intraperito-
neal xenografts (mean weight of mice, median carcinosis
score of the diaphragm, liver and intestine, mitotic index
or Ki67 percentage), we observed no proliferation increase
associated with the HA-CMC barrier. Our findings cor-
roborate other studies concerning non gynecological can-
cer in which HA-CMC barrier was described to protect
trocar sites from gall bladder metastasis and abdominal
wall implantation [32] while not decreasing overall sur-
vival for colon and rectal cancers [33].
However, our study does highlight that an i.p. HA-CMC
barrier implantation can induce a statistically significant
increase in the peritoneum carcinosis score (excluding
hemi diaphragm). While this was the only detected pejora-
tive impact of HA-CMC barrier, Hubbard et al. did pub-
lish similar findings for KM12-L4 colon cancer xenografts
in mice, observing a local increase in tumor volume in the
sidewall of the HA-CMC barrier and absorbable material
groups. This increase was thought to be due to local
Figure 4 Impact of HA-CMC barrier on ovarian s.c. tumor xenografts. (A) SKOV-3 cells were injected subcutaneously into the flanks of
immunosuppressed mice at day 0 (D0). At day 1 (D1), a 1 cm2 piece of HA-CMC barrier was inserted into one flank of each mouse (HA-CMC barrier), the
other flank being simply opened and closed again (control). Tumor volume was extrapolated from the measurement of tumor length and width every 2
or 3 days. (Mean tumor volume +/− SEM) 23 days after the injection, mice were sacrificed and tumors were sampled for histological analysis. (B) Mitotic
index was determined by counting the number of mitoses per 10 high-power fields. (C) Ki67 positive cells (%) were determined by Ki67 marking.
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biomaterial [8].
This result does warrant some concern, but such tumor
growth was isolated in our study. Human peritoneal carci-
nosis extension and resecability evaluation are respectively
performed with Sugarbaker and Fagotti scores but there
is no equivalent for murine carcinosis experimentation.
We decided to elaborate our own scoring system, which
is applicable macroscopically without any endoscopic orTable 1 Determination of the murine carcinosis index (MCI)
Maximal nodule diameter No visible disease
Diameter score 0
Nodule number 1-5 6-10
Number score 1 2
The MCI per organ (diaphragm, liver, peritoneum, digestive tract) is determined in m
nodule number score. The diameter score corresponds to the maximal nodule diam
number score corresponds to the number of nodules in the organ (from 1-5 noduleinformatics systems contrary to Matsuzaki published
score [31]. There were some differences between the
two double-blinded evaluation but the mean difference
concerning the peritoneal carcinosis score, which con-
stitutes the only localization apparently impacted by
HA-CMC barrier, was only 6.83%.
Since we were unable to highlight a clear implication
of HA-CMC barrier in ovarian tumor progression using
macroscopic parameters, we focused on a potential effect< 0.5 mm 0.5 to < 2 mm ≥ 2 mm
1 5 10
11-15 16-20 21-25 >25
3 4 5 6
ice by the following formula: total score = nodule maximal diameter score ×
eter (from non-visible nodules to nodules up to 2 mm diameter or over). The
s up to 25 nodules or over).
Figure 5 Impact of HA-CMC barrier on ovarian i.p. tumors xenograft. (A) SKOV-3 cells were injected intraperitoneally into the abdomen of
immunosuppressed mice. The day following the injection, half of the mice received a “white” laparotomy (control) and the other half underwent
a laparotomy with the insertion of a 2.25 cm2 piece of HA-CMC barrier (HA-CMC barrier). 21 days after the injection, mice were sacrificed and a
macroscopic analysis was performed in order to evaluate the median peritoneal carcinosis index for each of diaphragm, liver, peritoneum and
digestive tract. (Median +/− Extreme values, *p < 0.05) Tumors were sampled for histological analysis. (B) Mitotic index was determined by
counting the number of mitoses per 10 high-power fields. (C) Ki67 positive cells (%) were determined by Ki67 marking.
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we studied potential alteration in the expression of pro-
teins involved in cell survival (total Akt and phospho-Akt),
cell proliferation (phospho-ERK) and adhesion (FAK).
These signaling pathways have been described in the lit-
erature as being activated following AH-CD44 interactions
(PI3K-Akt [34], ERK [35] or FAK [36]). However we ob-
served no activation of these different pathways in the
HA-CMC barrier group of tumors by comparison with
control tumors thus confirming the lack of effect of this
biomaterial present on ovarian tumor behavior.
HA-CMC barrier-derived HA must therefore be differ-
entiated from extracellular endogenous HA, the expres-
sion of which favors the evolution of ovarian cancer
carcinosis. One of the possible explanations for the safety
of HA-CMC barrier-derived HA could be the difference
in its molecular weight compared to endogenous HA; highweight HA (4000 MDa) is anti-angiogenic and non-
immune response-inducing and low weight HA (10 MDa)
is pro-inflammatory, pro-angiogenic and immune response-
inducing [37]. Another explanation could be that HA-CMC
barrier HA shows less affinity for CD44-expressing tumor
cells. To test such a hypothesis, it would be interesting to
determine the phosphorylation status of CD44 receptors
in response to HA-CMC barrier placement in vitro. En-
dogenous HA effects are likely the consequence of several
interactions, not only with tumor cells but also with the
tumor microenvironment. Moreover, they may also de-
pend on their combined activation of surface receptors
with other extracellular matrix components such as vitro-
nectin or fibronectin.
We performed our in vivo experiments on nude mice
models. These animals presented a lack of mature T cells







































Figure 6 Effects of HA-CMC barrier on proliferation, survival
and adhesion signaling pathwasy in ovarian tumor xenografts.
s.c. and i.p. tumors were sampled the day the mice were sacrificed
and were grouped together according to experimental condition
(control or HA-CMC barrier). The Akt, phospho-Akt (p-Akt),
phospho-ERK (p-ERK) and FAK levels were determined by western
blot using a specific antibody. Immunocomplexes were visualized
with a photon camera.
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cells behavior in nude mice where macrophages, neutro-
phils and NK cells were present and responsible for a local
inflammation. Indeed, we showed an acute inflammatory
reaction 3 and 7 days after HA-CMC barrier injection in
nude mice. We concluded that the absence of T cells did
not alter the inflammation process in our model. Moreover,
the describing functions of all T cells subtypes (CD8+
T cells, T helpers cells, regulatory T cells and γδ T lym-
phocytes) in ovarian cancer progression showed opposite
roles [38]. So, we decided to work with immunodeficient
mice allowing the utilization of human tumor cells com-
pared to immunocompetent mice requiring murine cells.
Our results are worrisome because of MCI increase in
anterior and lateral peritoneum of HA-CMC barrier
treated mice. However, the clinical benefit of HA-CMC
barrier utilization is to our mind clearly established. First,
ovarian cancer bearing patients need to undergo multiple
surgeries that lead to the development of adherences
which constitute a complication risk factor. Secondly, in-
traperitoneal chemotherapy delivery cannot be performed
because of adherences which induce heterogeneity ofchemotherapy diffusion [3]. Because of benefit/risk bal-
ance, we decided to use this biomaterial for our patients
keeping in mind a clinical prospective study remains
necessary in order to clearly establish the harmlessness
of HA-CMC barrier.
Conclusion
In this study, we have shown that HA-CMC barrier
does not induce the proliferation of ovarian tumor cell
lines OVCAR-3, IGROV-1 and SKOV-3 in vitro. We
also highlighted that in vivo, with the exception of an-
terior and lateral peritoneum implantation, it does not
regulate ovarian tumor growth or dissemination of s.c.
or i.p. xenografts in mice. Moreover, HA-CMC barrier
did not activate microscopic cell proliferation (mitotic
index and Ki67 marking) or survival, proliferation and
adhesion signaling pathways. Only the median periton-
eal score (excluding hemi diaphragm) was increased by
HA-CMC barrier use. This effect was probably linked to
the inflammatory response due to exogenous biomaterial.
Altogether we conclude that HA-CMC barriers seem to
provide more benefits than potential oncological risks
even if we still cannot prove it does not increase locally
the growth of potentially residual tumor cells remaining
after surgery. The only way to confirm HA-CMC barriers
safety is to lead a prospective clinical study to assess nei-
ther recurrence rate increase nor disease-free survival de-
crease for extended ovarian cancer suffering patients.
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